Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma. LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -7.50p -5.84% 121.00p 120.00p 122.00p 125.50p 120.50p 124.50p 24,236 14:16:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 50.40

Destiny Pharma. Share Discussion Threads

Showing 1 to 20 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
02/11/2017
11:01
Up 10p were on our way to a doubling imho i hope
albanyvillas
02/11/2017
10:44
Dirty and sweet
albanyvillas
02/11/2017
10:41
Nice to see the 330p price target from broker
albanyvillas
02/11/2017
10:39
Houston this is Houston you read me We have launched a satellite
albanyvillas
02/11/2017
10:19
Northwards horatio
albanyvillas
02/11/2017
10:11
Destiny Pharma (BUY) – Prevention better than cure DEST LN (129p, TP 330p), Market Cap: £55m (Corporate Stock) Destiny Pharma’s lead programme is a novel anti-microbial targeting nasal de-colonisation of patients prior to surgery who harbour the potentially dangerous bacteria Staphylococcus aureus including the superbug MRSA. It is well documented that the majority of post-surgical infections are caused by a patient’s own bacteria principally residing in nasal passages. Consequently, new guidelines have emerged which recommend nasal de-colonisation prior to high-risk surgeries but the most widely used antibiotic suffers from significant limitations preventing widespread use. Destiny is developing a potent antimicrobial (XF-73) with several key attributes that suggest it could be optimally positioned to be the leader in a new FDA indication of prevention of post-surgical Staphylococcal infections. Clinical data has been persuasive providing a rapid bacterial kill combined with an unmatched resistance profile.
dewtrader
08/10/2017
11:08
rackers - not quite ... It's a binary bet, and to a non-specialist odds would be about 9:1 against success (statistical analysis of early-stage pharma without looking under the bonnet). But someone with subject knowledge can improve his odds selectively by looking at results to date and the people involved. For example, CEO Neil Clark was involved with steering CeNeS Pharma from 20 years ago. So weeding out the less likely candidates could shorten the odds to maybe 5:1. A dozen such companies invested in over a period could produce decent profits. I wouldn't follow someone like Woodford, who seems to invest in every IPO! And I've already given my reasons for leaving it alone. however, DrMaccers (who might be in the business) has convinced me of the best strategy here.
jonwig
08/10/2017
07:42
How anyone can invest in such an illiquid stock needs help.Not something any sane investor would touch I feel.
rackers1
03/10/2017
20:56
This needs to get past 2b before it's investible in really. Then it'll need a lot of cash for p3.Interesting but not more at this point in time or price
drmaccers
02/10/2017
13:47
At the risk of being a boor, I'll repeat my post #7 from four weeks ago: I saw the initial RNS and looked at the website. Basically their compounds appear to act so quickly that bacteria have no time to develop resistance via mutation. My immediate reaction to this was extreme scepticism. It appears to suggest that antibiotic resistant mutations happen when bacteria are stimulated by exposure to an agent. But this isn't the case: they happen purely randomly. Indeed there will already exist resistant strains, and resistant populations will develop and increase by natural selection as happens with current antibiotics. I met a biochemist last week (on holiday) whose discipline is immunology, so not quite the same, and he confirmed that my general understanding was correct. Obviously I need to do more study on this and it would be good to see if the company's research has been peer-reviewed. (A lot of these companies don't allow that.) I know their early trials have been successful, and I may be off-beam here, but I wouldn't want to invest in anything I didn't understand. I just can't find any corroborative information about their compounds (Help anyone?), and first results should be some time away. (How much?) Until then, it's unlikely the share price will do more than respond to speculative froth. A trigger will be phase results, and it's unlikely these can leak as they should be double-blind and reported immediately. When they are, how many here will understand them? More to the point, they seem to have £14m cash with a burn of £2m pa (but that will increase). At least they won't have to scramble.
jonwig
02/10/2017
13:27
AIM is not a market place for the patient, and with DEST set to be relatively quiet for at least 18 months, I guess its no surprise to see the initial euphoria fade quickly.
jack jebb
29/9/2017
16:16
Timberrrrr
rackers1
12/9/2017
11:11
Level 2 firming
albanyvillas
12/9/2017
08:30
DEST was changing hands at 240p last week Can be had at 180 now When she moves she moves
albanyvillas
08/9/2017
16:50
I saw the initial RNS and looked at the website. Basically their compounds appear to act so quickly that bacteria have no time to develop resistance via mutation. My immediate reaction to this was extreme scepticism. It appears to suggest that antibiotic resistant mutations happen when bacteria are stimulated by exposure to an agent. But this isn't the case: they happen purely randomly. Indeed there will already exist resistant strains, and resistant populations will develop and increase by natural selection as happens with current antibiotics. I met a biochemist last week (on holiday) whose discipline is immunology, so not quite the same, and he confirmed that my general understanding was correct. Obviously I need to do more study on this and it would be good to see if the company's research has been peer-reviewed. (A lot of these companies don't allow that.) I know their early trials have been successful, and I may be off-beam here, but I wouldn't want to invest in anything I didn't understand.
jonwig
06/9/2017
15:55
Hi Mod, Bamboo. I'd like to join the discussion if I may? I am a pre-IPO holder of DEST - invested in one the fundraising rounds back in 2013. So far so good!
kipper1960
05/9/2017
20:00
It was purely on a recommendation of a friend, it's a small gamble so happy to run with it.I am still very much upbeat about the market, my view is that the bull market will continue with some minor corrections along the way.
modform
05/9/2017
19:02
Cheers bamboo, hope you're on board
modform
05/9/2017
14:03
Https://www.destinypharma.com/wp-content/uploads/2017/08/Destiny-Pharma-Admission-Document.pdf
bamboo2
05/9/2017
14:03
Https://www.destinypharma.com/
bamboo2
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20171118 08:35:19